GSK Ends Advair Co-Promotion With Mistubishi Tanabe
This article was originally published in PharmAsia News
Executive Summary
GlaxoSmithKline will end a co-promotion deal with Mitsubishi Tanabe for Advair (fluticasone/salmeterol) by the end of July. Starting in August, GSK will be the sole marketer of the drug in Japan. The co-promotion started last April when GSK signed up Mitsubishi to promote Advair as the top treatment for chronic obstructive pulmonary disease in Japan. One year later, GSK said it had achieved the goal demonstrated by raised product awareness among medical facilities. Advair Japanese domestic sales reached ¥37.6 billion last year. The drug faces increasing competition in the dry powder inhaler market from Symbicort (budesonide/formoterol), which is being co-promoted by AstraZeneca and Astellas. Launched in January, Symbicort sales reached ¥1.5 billion at the end of March. (Click here for more - Japanese language) "GSK To Solely Market Adoair From August" - CB News (7/2/2010)
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.